Immunocore is one of the world’s leading biotechnology companies, with a highly innovative immune-oncology platform technology called ImmTAC.
ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecules are a new class of bi-specific biologic reagents that combine an affinity-enhanced T cell receptor (TCR)-based targeting system with an anti-CD3 (scFv) effector function to activate a highly potent and specific T cell response to recognise and destroy cancer cells.
For further information about ImmTAC click here.
IMCgp100 is Immunocore’s first ImmTAC molecule in Phase IIa clinical trials currently for the treatment of late-stage metastatic melanoma. This reagent comprises an affinity-enhanced T cell receptor (TCR) that recognises an HLA-A2-restricted peptide from the melanoma-associated antigen gp100, fused to an anti-CD3 single chain antibody fragment (scFv). For more information about this clinical trial, please visit https://clinicaltrials.gov
If you are a medical professional and require further information about Immunocore or our clinical research, please send an email to email@example.com. Patients are encouraged to contact their doctor ahead of contacting Immunocore including for questions regarding suitability or criteria for participating in a clinical trial or safety issues.
Additional information about our clinical research as well as timelines of the treatments being developed by Immunocore can be found here. Full disclosure of all trials are posted in Clinical trial databases in accordance with all industry guidelines.